Last-Resort drug linvoseltamab offered to myeloma patients with no other options
NCT ID NCT05164250
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This program provides linvoseltamab (REGN5458) to patients with relapsed or refractory multiple myeloma who have exhausted all standard treatments. The drug is a type of immunotherapy that helps the immune system attack cancer cells. It is given through compassionate use, meaning it is available outside of a clinical trial for those with no alternatives.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
linvoseltamab (REGN5458)
What this could lead to
If this treatment works, it could offer a new option for patients with multiple myeloma that has stopped responding to other therapies.
What could go wrong
This is a compassionate use program, not a formal trial, so data on safety and effectiveness is limited. The drug may not work for everyone and can cause serious side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.